Exagen Featured in Eight Scientific Presentations at the 2018 ACR/ARHP Annual Meeting in Chicago
Leading immunology laboratory continues strides with first ever economic impact data for AVISE Lupus
ALBUQUERQUE, NM and SAN DIEGO, CA, Oct 02, 2018 (GLOBE NEWSWIRE) – Exagen Diagostics, the exclusive providers of AVISE® testing, announced today that a total of eight scientific presentations have been accepted at this year’s 2018 ACR/ARHP Annual Meeting being held in Chicago, IL, October 19 – 24. The new data on display will highlight their proprietary lupus biomarkers, Cell-bound Complement Activation Products (CB-CAPs), as well as a first-of-its-kind health economic outcome evaluation of the impact AVISE Lupus can have on an earlier lupus diagnosis.
According to Dr. Thierry Dervieux, Chief Scientific Officer at Exagen, “We are proud to have our science recognized at such an important event as it will educate clinicians on the latest discoveries across the full spectrum of our advanced laboratory testing. If we look at the adoption rate of our tests within the rheumatology community, it is clear that doctors recognize the value we provide as a specialty reference lab and that is because we invest in the evidence to establish the clinical validity, clinical utility and impact on health economics of our assays for clinicians and payers.”
Exagen offers laboratory tests that address some of the most difficult to diagnose connective tissue diseases including lupus, where patients report waiting an average of 6 years for an accurate diagnosis from the time symptoms start. According to Ron Rocca, CEO at Exagen, “We are an organization that is patient focused, and discovery driven, so sharing 8 novel abstracts at the largest rheumatology conference in the world speaks to the very heart of what our organization has set out to do. Our goal is to improve the lives of patients, and that is why we continue to build on the already impressive body of evidence demonstrating the superiority of our advanced lab tests in diagnosis, prognosis and monitoring of patients with autoimmune conditions including connective tissue diseases, SLE and rheumatoid arthritis.”
Dr. Arthur Weinstein, Chief Medical Officer at Exagen explained, “These special tests from Exagen provide value to the Rheumatologist in a number of unique ways. First, there is a shortage of board-certified rheumatologists in the U.S. which is projected to worsen over the next few decades. This will result in ever longer wait times for an initial consultation. The proprietary assays and algorithms included in AVISE CTD can help to make rheumatologists more efficient in how they assess new patients referred for positive ANA test or suspected connective tissue diseases (CTD). Second, the use of the AVISE Lupus test has demonstrated superior performance to standard biomarkers alone and this new data reveals the cost savings from an earlier diagnosis of SLE. Third, patients of course will benefit from an earlier diagnosis and more appropriate therapy. Finally, the patented methotrexate polyglutamates assay helps optimize methotrexate dosing prior to advancing to higher cost biologic drugs or switching from one biologic to another. Clearly the broader adoption of AVISE testing results in a win – win – win situation for doctors, third-party payers, and most importantly patients.”
To learn more about Exagen Diagnostics, please visit www.Exagen.com.